Loading...
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
von Moos, R Hawle, H Hayoz, S Cathomas, R Muller, A Schmid, S Pagani, O Wehrhahn, T Rauch, D Anchisi, S
von Moos, R
Hawle, H
Hayoz, S
Cathomas, R
Muller, A
Schmid, S
Pagani, O
Wehrhahn, T
Rauch, D
Anchisi, S
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 109.22 KB
Keywords
Type
Meetings and Proceedings
Citation
von Moos R, Hawle H, Hayoz S, Cathomas R, M�ller A, Schmid S, et al. 1703P Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 2018;29(suppl_8).